

Resource Summary Report

Generated by [nidm-terms](#) on Aug 15, 2026

CD8

RRID:AB_1645481

Type: Antibody

Proper Citation

BD Biosciences Cat# 560179, RRID:AB_1645481

Antibody Information

URL: http://antibodyregistry.org/AB_1645481

Proper Citation: BD Biosciences Cat# 560179, RRID:AB_1645481

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: CD8

Description: This monoclonal targets CD8

Target Organism: human

Antibody ID: AB_1645481

Vendor: BD Biosciences

Catalog Number: 560179

Record Creation Time: 20250820T072104+0000

Record Last Update: 20250821T021018+0000

Ratings and Alerts

No rating or validation information has been found for CD8.

No alerts have been found for CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Gobran ST, et al. (2026) HCV-specific CD4+ T-cells are susceptible to HIV-1 and contribute to viral persistence during antiretroviral therapy. *EBioMedicine*, 130, 106365.

Song L, et al. (2025) Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC. *iScience*, 28(9), 113211.

Lebrec H, et al. (2025) Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease. *iScience*, 28(5), 112447.

Gonnella G, et al. (2025) Immune profiling in subclinical secondary dengue-infected cases reveals adaptive immune signatures correlated to protection from severe dengue. *Cell host & microbe*, 33(7), 1191.

Jeon SH, et al. (2025) Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(21), 4586.

Codazzi V, et al. (2025) Metabolic, genetic and immunological features of relatives of type 1 diabetes patients with elevated insulin resistance. *Journal of endocrinological investigation*, 48(3), 765.

Lindahl H, et al. (2025) Extensive Clinical Flow Cytometric Lymphocyte Phenotyping in Myasthenia Gravis: A Single-Center Study. *Journal of neurochemistry*, 169(6), e70126.

Kleist AB, et al. (2025) Encoding and decoding selectivity and promiscuity in the human chemokine-GPCR interaction network. *Cell*, 188(13), 3603.

Lin S, et al. (2025) Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. *iScience*, 28(5), 112497.

Hsu AY, et al. (2025) Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution. *Cell*, 188(6), 1623.

Aznar MA, et al. (2025) Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. *Cell reports. Medicine*, 6(9), 102301.

Das Adhikari U, et al. (2025) Immunometabolic defects of CD8+ T cells disrupt gut barrier integrity in people with HIV. *Cell*.

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. *Cell reports. Medicine*, 102360.

Giovenzana A, et al. (2024) Fat-to-blood recirculation of partially dysfunctional PD-1+CD4 Tconv cells is associated with dysglycemia in human obesity. *iScience*, 27(3), 109032.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. *Cell reports. Medicine*, 5(11), 101823.

Zoine JT, et al. (2024) Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity. *Cell reports. Medicine*, 5(2), 101422.

Tretter C, et al. (2023) Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification. *Nature communications*, 14(1), 4632.

Lozano-Rabella M, et al. (2023) Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(12), 2250.

Agarwal S, et al. (2023) Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. *Immunity*, 56(10), 2388.

Bergaggio E, et al. (2023) ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. *Cancer cell*, 41(12), 2100.